Recursion uses artificial intelligence to help advance drug discovery, which could be a massive opportunity in healthcare.

Recursion Pharmaceuticals shows high cash burn, limited efficacy data, and unproven platform validation. Check out why RXRX ...

It's tough to get excited about buying most growth stocks right now. Too many of them are just too expensive relative to the ...

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2025 ...

In this week’s edition of InnovationRx, we look Nvidia’s collaborations in life sciences and drug development, Cobot’s ...

The support network that has emerged through the Mises Institute is really important. We feel like we’re all alone, but ...

Bristol Myers Squibb is shedding two clinical programs, one from its 2023 Mirati buyout and another from a partnership with U ...

By Yuen Yuen Ang Conflicts, trade wars, inequality, and democratic decay fill today’s headlines. Each crisis appears to be ...

The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark ...

Recursion Pharmaceuticals (RXRX) shares ended the last trading session 8.2% higher at $5.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...